{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T16:14:10Z","timestamp":1793031250137,"version":"4.5.0"},"reference-count":111,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001511","name":"Auckland Medical Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001511","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001537","name":"University of Auckland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001537","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.drudis.2019.03.023","type":"journal-article","created":{"date-parts":[[2019,3,28]],"date-time":"2019-03-28T12:49:07Z","timestamp":1553777347000},"page":"1458-1469","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":53,"title":["Depot formulations to sustain periocular drug delivery to the posterior eye segment"],"prefix":"10.1016","volume":"24","author":[{"given":"Yosra","family":"Agban","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachin S.","family":"Thakur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Odunayo O.","family":"Mugisho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5997-5994","authenticated-orcid":false,"given":"Ilva D.","family":"Rupenthal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2019.03.023_bib0005","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1136\/bjophthalmol-2011-300539","article-title":"Global estimates of visual impairment: 2010","volume":"96","author":"Pascolini","year":"2012","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.drudis.2019.03.023_bib0010","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/j.addr.2006.07.027","article-title":"Challenges and obstacles of ocular pharmacokinetics and drug delivery","volume":"58","author":"Urtti","year":"2006","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.drudis.2019.03.023_bib0015","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.addr.2017.09.008","article-title":"Overcoming ocular drug delivery barriers through the use of physical forces","volume":"126","author":"Huang","year":"2018","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.drudis.2019.03.023_bib0020","doi-asserted-by":"crossref","first-page":"685","DOI":"10.4155\/tde-2017-0097","article-title":"Posterior drug delivery via periocular route: challenges and opportunities","volume":"8","author":"Waite","year":"2017","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.drudis.2019.03.023_bib0025","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1517\/17425247.2014.927864","article-title":"Intravitreal drug delivery in retinal disease: are we out of our depth?","volume":"11","author":"Thakur","year":"2014","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.drudis.2019.03.023_bib0030","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.survophthal.2004.12.006","article-title":"Applications of liposomes in ophthalmology","volume":"50","author":"Ebrahim","year":"2005","journal-title":"Surv. Ophthalmol."},{"key":"10.1016\/j.drudis.2019.03.023_bib0035","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0002-9394(99)80096-8","article-title":"Human sclera: thickness and surface area","volume":"125","author":"Olsen","year":"1998","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.drudis.2019.03.023_bib0040","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1517\/17425247.1.1.99","article-title":"Periocular routes for retinal drug delivery","volume":"1","author":"Raghava","year":"2004","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.drudis.2019.03.023_bib0045","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.jmbbm.2017.10.024","article-title":"The elastic modulus and collagen of sclera increase during the early growth process","volume":"77","author":"Wang","year":"2018","journal-title":"J. Mech. Behav. Biomed. Mater."},{"key":"10.1016\/j.drudis.2019.03.023_bib0050","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S0014-4835(03)00212-4","article-title":"Scleral structure, organisation and disease. A review","volume":"78","author":"Watson","year":"2004","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.drudis.2019.03.023_bib0055","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/j.1442-9071.2011.02745.x","article-title":"Anatomy of Tenons capsule","volume":"40","author":"Kakizaki","year":"2012","journal-title":"Clin. Exp. Ophthalmol."},{"key":"10.1016\/j.drudis.2019.03.023_bib0060","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1517\/17425247.4.4.371","article-title":"Novel approaches to retinal drug delivery","volume":"4","author":"Janoria","year":"2007","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.drudis.2019.03.023_bib0065","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1208\/s12248-010-9183-3","article-title":"Ocular drug delivery","volume":"12","author":"Gaudana","year":"2010","journal-title":"AAPS J."},{"key":"10.1016\/j.drudis.2019.03.023_bib0070","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1016\/S0161-6420(00)00344-4","article-title":"Dexamethasone concentration in the subretinal fluid after a subconjunctival injection, a peribulbar injection, or an oral dose","volume":"107","author":"Weijtens","year":"2000","journal-title":"Ophthalmology"},{"key":"10.1016\/j.drudis.2019.03.023_bib0075","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2147\/LRA.S16314","article-title":"Sub-Tenon\u2019s anesthesia: an update","volume":"5","author":"Guise","year":"2012","journal-title":"Local Reg. Anesth."},{"key":"10.1016\/j.drudis.2019.03.023_bib0080","doi-asserted-by":"crossref","first-page":"773","DOI":"10.3928\/1542-8877-19960901-08","article-title":"Sub-Tenon\u2019s versus retrobulbar anesthesia for cataract surgery","volume":"27","author":"Khoo","year":"1996","journal-title":"Ophthalmic Surg. Lasers"},{"issue":"Suppl. 1","key":"10.1016\/j.drudis.2019.03.023_bib0085","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1016\/j.survophthal.2006.10.015","article-title":"Anecortave acetate clinical study G. Posterior juxtascleral depot administration of anecortave acetate","volume":"52","author":"Kaiser","year":"2007","journal-title":"Surv. Ophthalmol."},{"key":"10.1016\/j.drudis.2019.03.023_bib0090","doi-asserted-by":"crossref","first-page":"237","DOI":"10.2147\/ciia.2006.1.3.237","article-title":"Anecortave acetate in the treatment of age-related macular degeneration","volume":"1","author":"Augustin","year":"2006","journal-title":"Clin. Interv. Aging"},{"issue":"Suppl. 1","key":"10.1016\/j.drudis.2019.03.023_bib0095","doi-asserted-by":"crossref","first-page":"S70","DOI":"10.1016\/j.survophthal.2006.11.001","article-title":"Clinical safety profile of posterior juxtascleral depot administration of anecortave acetate 15\u2009mg suspension as primary therapy or adjunctive therapy with photodynamic therapy for treatment of wet age-related macular degeneration","volume":"52","author":"Regillo","year":"2007","journal-title":"Surv. Ophthalmol."},{"key":"10.1016\/j.drudis.2019.03.023_bib0100","series-title":"The Musculoskeletal System","first-page":"123","article-title":"Autoimmunity and the musculoskeletal system","author":"Manolios","year":"2010"},{"key":"10.1016\/j.drudis.2019.03.023_bib0105","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1007\/s11095-010-0237-0","article-title":"Influence of permeant lipophilicity on permeation across human sclera","volume":"27","author":"Wen","year":"2010","journal-title":"Pharm. Res."},{"key":"10.1016\/j.drudis.2019.03.023_bib0110","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1159\/000108117","article-title":"Transport barriers in transscleral drug delivery for retinal diseases","volume":"39","author":"Kim","year":"2007","journal-title":"Ophthalmic Res."},{"key":"10.1016\/j.drudis.2019.03.023_bib0115","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jconrel.2010.08.028","article-title":"Barrier analysis of periocular drug delivery to the posterior segment","volume":"148","author":"Ranta","year":"2010","journal-title":"J. Control. Release"},{"key":"10.1016\/j.drudis.2019.03.023_bib0120","first-page":"1186","article-title":"Transscleral delivery of bioactive protein to the choroid and retina","volume":"41","author":"Ambati","year":"2000","journal-title":"Invest Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.drudis.2019.03.023_bib0125","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1002\/jps.23387","article-title":"Characterization of human sclera barrier properties for transscleral delivery of bevacizumab and ranibizumab","volume":"102","author":"Wen","year":"2013","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.drudis.2019.03.023_bib0130","first-page":"1181","article-title":"Diffusion of high molecular weight compounds through sclera","volume":"41","author":"Ambati","year":"2000","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.drudis.2019.03.023_bib0135","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ijpharm.2009.12.046","article-title":"Iontophoretic transport of charged macromolecules across human sclera","volume":"388","author":"Chopra","year":"2010","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.drudis.2019.03.023_bib0140","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1021\/js9802594","article-title":"Permeability of cornea, sclera, and conjunctiva: a literature analysis for drug delivery to the eye","volume":"87","author":"Prausnitz","year":"1998","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.drudis.2019.03.023_bib0145","first-page":"259","article-title":"Porcine sclera as a model of human sclera for in vitro transport experiments: histology, SEM, and comparative permeability","volume":"15","author":"Nicoli","year":"2009","journal-title":"Mol. Vis."},{"key":"10.1016\/j.drudis.2019.03.023_bib0150","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1089\/jop.2008.0010","article-title":"Drug delivery to the posterior segment of the eye IV: theoretical formulation of a drug delivery system for subconjunctival injection","volume":"25","author":"Wai-Yip Lee","year":"2009","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"10.1016\/j.drudis.2019.03.023_bib0155","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1167\/iovs.03-0765","article-title":"The influence of path length and matrix components on ageing characteristics of transport between the choroid and the outer retina","volume":"45","author":"Hillenkamp","year":"2004","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.drudis.2019.03.023_bib0160","first-page":"2857","article-title":"Morphometric analysis of Bruch\u2019s membrane, the choriocapillaris, and the choroid in aging","volume":"35","author":"Ramrattan","year":"1994","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.drudis.2019.03.023_bib0165","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1167\/iovs.06-0954","article-title":"Pharmacokinetics of intraocular drug delivery by periocular injections using ocular fluorophotometry","volume":"48","author":"Ghate","year":"2007","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.drudis.2019.03.023_bib0170","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.exer.2005.08.007","article-title":"A rabbit model for assessing the ocular barriers to the transscleral delivery of triamcinolone acetonide","volume":"82","author":"Robinson","year":"2006","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.drudis.2019.03.023_bib0175","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1007\/s11095-007-9408-z","article-title":"Drug elimination kinetics following subconjunctival injection using dynamic contrast-enhanced magnetic resonance imaging","volume":"25","author":"Kim","year":"2008","journal-title":"Pharm. Res."},{"key":"10.1016\/j.drudis.2019.03.023_bib0180","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S0886-3350(03)00161-5","article-title":"Conjunctival lymphatic system","volume":"29","author":"Singh","year":"2003","journal-title":"J. Cataract Refract. Surg."},{"key":"10.1016\/j.drudis.2019.03.023_bib0185","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1097\/00002341-199907000-00006","article-title":"Identification of human orbital lymphatics","volume":"15","author":"Gausas","year":"1999","journal-title":"Ophthalmic Plast. Reconstr. Surg."},{"key":"10.1016\/j.drudis.2019.03.023_bib0190","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.1167\/iovs.06-0030","article-title":"Delivery from episcleral exoplants","volume":"47","author":"De Carvalho","year":"2006","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.drudis.2019.03.023_bib0195","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1021\/acs.molpharmaceut.6b00782","article-title":"LC\u2013MS\/MS based quantitation of ABC and SLC Transporter Proteins in plasma membranes of cultured primary human retinal pigment epithelium cells and immortalized ARPE19 cell line","volume":"14","author":"Pelkonen","year":"2017","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.drudis.2019.03.023_bib0200","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1517\/17425255.2013.796928","article-title":"Advances in the understanding of retinal drug disposition and the role of blood\u2013ocular barrier transporters","volume":"9","author":"Jord\u00e1n","year":"2013","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.drudis.2019.03.023_bib0205","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S0014-4835(86)80029-X","article-title":"The movement of organic solutes between the retina and pigment-epithelium","volume":"43","author":"Sellner","year":"1986","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.drudis.2019.03.023_bib0210","series-title":"Transporters and Receptors in Ocular Drug Delivery: Opportunities and Challenges","author":"Dey","year":"2005"},{"key":"10.1016\/j.drudis.2019.03.023_bib0215","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1016\/j.addr.2006.07.024","article-title":"Drug transport in corneal epithelium and blood\u2013retina barrier: emerging role of transporters in ocular pharmacokinetics","volume":"58","author":"Mannermaa","year":"2006","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.drudis.2019.03.023_bib0220","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1167\/iovs.05-0189","article-title":"Characterization of brimonidine transport in retinal pigment epithelium","volume":"47","author":"Zhang","year":"2006","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.drudis.2019.03.023_bib0225","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1076\/ceyr.28.3.159.26244","article-title":"Expression of glutamate transporter subtypes in cultured retinal pigment epithelial and retinoblastoma cells","volume":"28","author":"Maenpaa","year":"2004","journal-title":"Curr. Eye Res."},{"key":"10.1016\/j.drudis.2019.03.023_bib0230","doi-asserted-by":"crossref","first-page":"4529","DOI":"10.1167\/iovs.04-0919","article-title":"Taurine uptake by human retinal pigment epithelium: Implications for the transport of small solutes between the choroid and the outer retina","volume":"45","author":"Hillenkamp","year":"2004","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.drudis.2019.03.023_bib0235","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.addr.2012.09.027","article-title":"Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview","volume":"64","author":"Schinkel","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.drudis.2019.03.023_bib0240","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1167\/iovs.04-0925","article-title":"Functional characterization and comparison of the outer blood\u2013retina barrier and the blood\u2013brain barrier","volume":"46","author":"Steuer","year":"2005","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.drudis.2019.03.023_bib0245","doi-asserted-by":"crossref","first-page":"7468","DOI":"10.1038\/sj.onc.1206948","article-title":"P-glycoprotein: from genomics to mechanism","volume":"22","author":"Ambudkar","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.drudis.2019.03.023_bib0250","first-page":"422","article-title":"P-glycoprotein expression in human retinal pigment epithelium","volume":"8","author":"Kennedy","year":"2002","journal-title":"Mol. Vis."},{"key":"10.1016\/j.drudis.2019.03.023_bib0255","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1007\/s11095-009-9890-6","article-title":"Efflux protein expression in human retinal pigment epithelium cell lines","volume":"26","author":"Mannermaa","year":"2009","journal-title":"Pharm. Res."},{"key":"10.1016\/j.drudis.2019.03.023_bib0260","doi-asserted-by":"crossref","first-page":"7537","DOI":"10.1038\/sj.onc.1206953","article-title":"The MRP family of drug efflux pumps","volume":"22","author":"Kruh","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.drudis.2019.03.023_bib0265","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1007\/s11095-007-9453-7","article-title":"Multichannel liquid chromatography-tandem mass spectrometry cocktail method for comprehensive substrate characterization of multidrug resistance-associated protein 4 transporter","volume":"24","author":"Uchida","year":"2007","journal-title":"Pharm. Res."},{"key":"10.1016\/j.drudis.2019.03.023_bib0270","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1007\/s00228-012-1394-3","article-title":"Importance of cytochrome P450 (CYP450) in adverse drug reactions due to drug-drug interactions: a PharmacoVigilance study in France","volume":"69","author":"Danton","year":"2013","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.drudis.2019.03.023_bib0275","doi-asserted-by":"crossref","first-page":"623","DOI":"10.3109\/02713688709025223","article-title":"Cytochrome P450, drug metabolizing enzymes and arachidonic acid metabolism in bovine ocular tissues","volume":"6","author":"Schwartzman","year":"1987","journal-title":"Curr. Eye Res."},{"key":"10.1016\/j.drudis.2019.03.023_bib0280","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0169-409X(99)00065-4","article-title":"Lysosome membrane permeability: implications for drug delivery","volume":"41","author":"Lloyd","year":"2000","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.drudis.2019.03.023_bib0285","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1517\/17425247.2.5.891","article-title":"Ophthalmic drug delivery considerations at the cellular level: drug-metabolising enzymes and transporters","volume":"2","author":"Attar","year":"2005","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.drudis.2019.03.023_bib0290","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/j.1600-0749.1993.tb00591.x","article-title":"Interaction between chemicals and melanin","volume":"6","author":"Larsson","year":"1993","journal-title":"Pigm. Cell Res."},{"key":"10.1016\/j.drudis.2019.03.023_bib0295","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1006\/rtph.1998.1243","article-title":"Binding of drugs to eye melanin is not predictive of ocular toxicity","volume":"28","author":"Leblanc","year":"1998","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.drudis.2019.03.023_bib0300","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.ejps.2012.03.013","article-title":"Ex vivo models to evaluate the role of ocular melanin in trans-scleral drug delivery","volume":"46","author":"Pescina","year":"2012","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.drudis.2019.03.023_bib0305","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0939-6411(97)00166-5","article-title":"Significance of melanin binding and metabolism in the activity of 5-acetoxyacetylimino-4-methyl-\u03942-1, 3, 4,-thiadiazoline-2-sulfonamide1","volume":"46","author":"Schoenwald","year":"1998","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.drudis.2019.03.023_bib0310","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.exer.2012.03.004","article-title":"Intraocular distribution of melanin in human, monkey, rabbit, minipig and dog eyes","volume":"98","author":"Durairaj","year":"2012","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.drudis.2019.03.023_bib0315","first-page":"710","article-title":"Colloidal drug delivery system: amplify the ocular delivery","volume":"23","author":"Ali","year":"2016","journal-title":"Drug Deliv."},{"key":"10.1016\/j.drudis.2019.03.023_bib0320","doi-asserted-by":"crossref","DOI":"10.1167\/iovs.01-1156","article-title":"Controlled delivery of the anti-VEGF aptamer EYE001 with poly(lactic-co-glycolic)acid microspheres","volume":"44","author":"Carrasquillo","year":"2003","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.drudis.2019.03.023_bib0325","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1167\/iovs.02-0791","article-title":"Subconjunctival nano- and microparticles sustain retinal delivery of budesonide, a corticosteroid capable of inhibiting VEGF expression","volume":"44","author":"Kompella","year":"2003","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.drudis.2019.03.023_bib0330","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.ejphar.2005.02.019","article-title":"Subconjunctivally administered celecoxib-PLGA microparticles sustain retinal drug levels and alleviate diabetes-induced oxidative stress in a rat model","volume":"511","author":"Ayalasomayajula","year":"2005","journal-title":"Eur. J. Pharmacol"},{"key":"10.1016\/j.drudis.2019.03.023_bib0335","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1001\/archophthalmol.2009.185","article-title":"Subconjunctival nanoparticle carboplatin in the treatment of murine retinoblastoma","volume":"127","author":"Kang","year":"2009","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.drudis.2019.03.023_bib0340","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/S0168-3659(03)00151-2","article-title":"Transscleral permeability and intraocular concentrations of cisplatin from a collagen matrix","volume":"89","author":"Gilbert","year":"2003","journal-title":"J. Control. Release"},{"key":"10.1016\/j.drudis.2019.03.023_bib0345","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1089\/jop.2009.0059","article-title":"Sustained subconjunctival protein delivery using a thermosetting gel delivery system","volume":"26","author":"Rieke","year":"2010","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"10.1016\/j.drudis.2019.03.023_bib0350","doi-asserted-by":"crossref","first-page":"6541","DOI":"10.1016\/j.biomaterials.2009.08.025","article-title":"Subconjunctivally implantable hydrogels with degradable and thermoresponsive properties for sustained release of insulin to the retina","volume":"30","author":"Misra","year":"2009","journal-title":"Biomaterials"},{"key":"10.1016\/j.drudis.2019.03.023_bib0355","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.ejps.2011.08.026","article-title":"In-vitro and in-vivo evaluation of carrageenan\/methylcellulose polymeric systems for transscleral delivery of macromolecules","volume":"44","author":"Thrimawithana","year":"2011","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.drudis.2019.03.023_bib0360","doi-asserted-by":"crossref","first-page":"849","DOI":"10.3109\/10717544.2014.919543","article-title":"A study of the dexamethasone sodium phosphate release properties from a periocular capsular drug delivery system","volume":"23","author":"Huang","year":"2016","journal-title":"Drug Deliv."},{"key":"10.1016\/j.drudis.2019.03.023_bib0365","doi-asserted-by":"crossref","first-page":"585","DOI":"10.4103\/0301-4738.129792","article-title":"Carboplatin loaded polymethylmethacrylate nano-particles in an adjunctive role in retinoblastoma: an animal trial","volume":"62","author":"Shome","year":"2014","journal-title":"Ind. J. Ophthalmol."},{"key":"10.1016\/j.drudis.2019.03.023_bib0370","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1076\/ceyr.16.9.930.5042","article-title":"Biodegradable scleral implant for intravitreal controlled release of fluconazole","volume":"16","author":"Miyamoto","year":"1997","journal-title":"Curr. Eye Res."},{"key":"10.1016\/j.drudis.2019.03.023_bib0375","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1007\/s004170050031","article-title":"Biodegradable scleral implant for intravitreal controlled release of ganciclovir","volume":"238","author":"Yasukawa","year":"2000","journal-title":"Graef. Arch. Clin. Exp. Ophthalmol."},{"key":"10.1016\/j.drudis.2019.03.023_bib0380","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1167\/iovs.02-0375","article-title":"Biodegradable intrascleral implant for sustained intraocular delivery of betamethasone phosphate","volume":"44","author":"Okabe","year":"2003","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.drudis.2019.03.023_bib0385","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1167\/iovs.02-0956","article-title":"Intraocular tissue distribution of betamethasone after intrascleral administration using a non-biodegradable sustained drug delivery device","volume":"44","author":"Okabe","year":"2003","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.drudis.2019.03.023_bib0390","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1167\/iovs.02-1258","article-title":"Feasibility of drug delivery to the posterior pole of the rabbit eye with an episcleral implant","volume":"45","author":"Kato","year":"2004","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.drudis.2019.03.023_bib0395","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ijpharm.2006.05.053","article-title":"Biodegradable scleral implants as new triamcinolone acetonide delivery systems","volume":"322","author":"Felt-Baeyens","year":"2006","journal-title":"Int. J. Pharmaceut"},{"key":"10.1016\/j.drudis.2019.03.023_bib0400","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ejpb.2008.04.023","article-title":"A novel design of one-side coated biodegradable intrascleral implant for the sustained release of triamcinolone acetonide","volume":"70","author":"Kim","year":"2008","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.drudis.2019.03.023_bib0405","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1016\/j.biomaterials.2010.11.006","article-title":"A scalable controlled-release device for transscleral drug delivery to the retina","volume":"32","author":"Kawashima","year":"2011","journal-title":"Biomaterials"},{"key":"10.1016\/j.drudis.2019.03.023_bib0410","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0058580","article-title":"Transscleral sustained vasohibin-1 delivery by a novel device suppressed experimentally-induced choroidal neovascularization","volume":"8","author":"Onami","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.drudis.2019.03.023_bib0415","first-page":"p471","article-title":"Transscleral controlled delivery of geranylgeranylaceton using a polymeric device protects rat retina against light injury","volume":"854","author":"Nagai","year":"2016"},{"key":"10.1016\/j.drudis.2019.03.023_bib0420","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.actbio.2013.11.004","article-title":"A polymeric device for controlled transscleral multi-drug delivery to the posterior segment of the eye","volume":"10","author":"Nagai","year":"2014","journal-title":"Acta Biomater."},{"key":"10.1016\/j.drudis.2019.03.023_bib0425","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.201400114","article-title":"A platform for controlled dual-drug delivery to the retina: protective effects against light-induced retinal damage in rats","volume":"3","author":"Nagai","year":"2014","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.drudis.2019.03.023_bib0430","doi-asserted-by":"crossref","first-page":"6527","DOI":"10.1167\/iovs.16-20453","article-title":"Long-term protection of genetically ablated rabbit retinal degeneration by sustained transscleral unoprostone delivery","volume":"57","author":"Nagai","year":"2016","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.drudis.2019.03.023_bib0435","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1167\/iovs.17-22429","article-title":"Pharmacokinetic and safety evaluation of a transscleral sustained unoprostone release device in monkey eyes","volume":"59","author":"Nagai","year":"2018","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.drudis.2019.03.023_bib0440","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.actbio.2013.09.022","article-title":"Sustained release of triamcinolone acetonide from an episcleral plaque of multilayered poly-\u03b5-caprolactone matrix","volume":"10","author":"Meng","year":"2014","journal-title":"Acta Biomater."},{"key":"10.1016\/j.drudis.2019.03.023_bib0445","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1111\/jphp.12152","article-title":"Microneedle-mediated intrascleral delivery of in situ forming thermoresponsive implants for sustained ocular drug delivery","volume":"66","author":"Thakur","year":"2014","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.drudis.2019.03.023_bib0450","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s11095-008-9756-3","article-title":"Intrascleral drug delivery to the eye using hollow microneedles","volume":"26","author":"Jiang","year":"2009","journal-title":"Pharm. Res."},{"key":"10.1016\/j.drudis.2019.03.023_bib0455","doi-asserted-by":"crossref","first-page":"4038","DOI":"10.1167\/iovs.07-0066","article-title":"Coated microneedles for drug delivery to the eye","volume":"48","author":"Jiang","year":"2007","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.drudis.2019.03.023_bib0460","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1007\/s13346-016-0332-9","article-title":"Rapidly dissolving polymeric microneedles for minimally invasive intraocular drug delivery","volume":"6","author":"Thakur","year":"2016","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.drudis.2019.03.023_bib0465","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1167\/iovs.13-11747","article-title":"Treatment of acute posterior uveitis in a porcine model by injection of triamcinolone acetonide into the suprachoroidal space using microneedles","volume":"54","author":"Gilger","year":"2013","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.drudis.2019.03.023_bib0470","doi-asserted-by":"crossref","first-page":"4433","DOI":"10.1167\/iovs.12-9872","article-title":"Targeted administration into the suprachoroidal space using a microneedle for drug delivery to the posterior segment of the eye","volume":"53","author":"Patel","year":"2012","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.drudis.2019.03.023_bib0475","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/s11095-010-0271-y","article-title":"Suprachoroidal drug delivery to the back of the eye using hollow microneedles","volume":"28","author":"Patel","year":"2011","journal-title":"Pharm. Res."},{"key":"10.1016\/j.drudis.2019.03.023_bib0480","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1021\/mp300716t","article-title":"Light-activated, in situ forming gel for sustained suprachoroidal delivery of bevacizumab","volume":"10","author":"Tyagi","year":"2013","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.drudis.2019.03.023_bib0485","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1211\/jpp.57.12.0005","article-title":"Size-dependent disposition of nanoparticles and microparticles following subconjunctival administration","volume":"57","author":"Amrite","year":"2005","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.drudis.2019.03.023_bib0490","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jconrel.2015.05.279","article-title":"Novel biodegradable polyesteramide microspheres for controlled drug delivery in ophthalmology","volume":"211","author":"Andres-Guerrero","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.drudis.2019.03.023_bib0495","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1038\/nbt1171","article-title":"Designing dendrimers for biological applications","volume":"23","author":"Lee","year":"2005","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.drudis.2019.03.023_bib0500","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1089\/jop.2012.0232","article-title":"Dendrimer nanoparticles for ocular drug delivery","volume":"29","author":"Kambhampati","year":"2013","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"10.1016\/j.drudis.2019.03.023_bib0505","doi-asserted-by":"crossref","first-page":"159","DOI":"10.15171\/bi.2015.31","article-title":"Hydrogels for ocular drug delivery and tissue engineering","volume":"5","author":"Fathi","year":"2015","journal-title":"Bioimpacts"},{"key":"10.1016\/j.drudis.2019.03.023_bib0510","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.drudis.2013.01.013","article-title":"Injectable implants for the sustained release of protein and peptide drugs","volume":"18","author":"Agarwal","year":"2013","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.drudis.2019.03.023_bib0515","doi-asserted-by":"crossref","first-page":"7839","DOI":"10.1167\/iovs.15-16998","article-title":"Subconjunctivally implanted hydrogels for sustained insulin release to reduce retinal cell apoptosis in diabetic rats","volume":"56","author":"Imai","year":"2015","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.drudis.2019.03.023_bib0520","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.3390\/ijms18122567","article-title":"Immunohistochemical Characterization of connexin43 expression in a mouse model of diabetic retinopathy and in human donor retinas","volume":"18","author":"Mugisho","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.drudis.2019.03.023_bib0525","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s10856-017-5919-2","article-title":"Physicochemical and biological characterization of sustained isopropyl unoprostone-release device made of poly(ethyleneglycol) dimethacrylates","volume":"28","author":"Nagai","year":"2017","journal-title":"J. Mater. Sci. Mater. Med."},{"key":"10.1016\/j.drudis.2019.03.023_bib0530","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.addr.2018.03.001","article-title":"The suprachoroidal space as a route of administration to the posterior segment of the eye","volume":"126","author":"Chiang","year":"2018","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.drudis.2019.03.023_bib0535","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.drudis.2014.10.010","article-title":"The suprachoroidal pathway: a new drug delivery route to the back of the eye","volume":"20","author":"Rai Udo","year":"2015","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.drudis.2019.03.023_bib0540","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1080\/17425247.2016.1218460","article-title":"Minimally invasive microneedles for ocular drug delivery","volume":"14","author":"Thakur Singh","year":"2017","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.drudis.2019.03.023_bib0545","doi-asserted-by":"crossref","first-page":"790","DOI":"10.3109\/1061186X.2014.921926","article-title":"Smart microneedle coatings for controlled delivery and biomedical analysis","volume":"22","author":"Khan","year":"2014","journal-title":"J. Drug Target."},{"key":"10.1016\/j.drudis.2019.03.023_bib0550","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ejpb.2019.01.005","article-title":"Recent advances in microneedle-based drug delivery: special emphasis on its use in paediatric population","volume":"136","author":"Duarah","year":"2019","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.drudis.2019.03.023_bib0555","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ejps.2014.09.011","article-title":"Investigation on fabrication process of dissolving microneedle arrays to improve effective needle drug distribution","volume":"66","author":"Wang","year":"2015","journal-title":"Eur. J. Pharm. Sci."}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644618303945?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644618303945?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T12:39:25Z","timestamp":1761223165000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644618303945"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":111,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["S1359644618303945"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2019.03.023","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Depot formulations to sustain periocular drug delivery to the posterior eye segment","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2019.03.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}